Drugs that contain Panobinostat Lactate

1. Farydak patents expiration

FARYDAK's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7989494 SECURA Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
Jan, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883842 SECURA Use of HDAC inhibitors for the treatment of myeloma
Jun, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 23, 2022

Market Authorisation Date: 23 February, 2015

Treatment: Treatment of multiple myeloma, in combination with bortezomib and dexamethasone


More Information on Dosage

FARYDAK family patents

Family Patents